Paris - Paris Delayed Price. Currency in EUR


60 Avenue Rockefeller
Lyon 69008
33 4 78 74 44 38

Full Time Employees172

Key Executives

NameTitlePayExercisedYear Born
Mr. Gil Beyen BVBACEO & Director456.42kN/A1962
Mr. Jérôme Bailly Pharm.D.VP, Director of Pharmaceutical Operations & Deputy GM234.28kN/A1979
Mr. Eric Soyer Ph.D.CFO, COO & Deputy GMN/AN/A1966
Dr. Alexander ScheerChief Scientific OfficerN/AN/A1962
Naomi EichenbaumDirector Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for severe forms of cancer and orphan diseases. The company's lead product candidate is eryaspase, which is in Phase III clinical development for the treatment of second-line pancreatic cancer and in Phase II stage for the treatment of triple-negative breast cancer. ERYTECH Pharma S.A. has research collaboration with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. ERYTECH Pharma S.A. was founded in 2004 and is headquartered in Lyon, France.

Corporate Governance

ERYTECH Pharma S.A.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.